News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
263,390 Results
Type
Article (13451)
Company Profile (31)
Press Release (249905)
Multimedia
Podcasts (78)
Webinars (6)
Section
Business (71442)
Career Advice (462)
Deals (14529)
Drug Delivery (75)
Drug Development (36924)
Employer Resources (45)
FDA (9676)
Job Trends (6652)
News (133603)
Policy (13323)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (1)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (2)
2027 Pharm Country Standard (1)
Academia (880)
Accelerated approval (24)
Adcomms (11)
Allergies (77)
Alliances (18627)
ALS (96)
Alzheimer's disease (906)
Antibody-drug conjugate (ADC) (169)
Approvals (9926)
Artificial intelligence (233)
Autoimmune disease (85)
Automation (15)
Bankruptcy (137)
Best Places to Work (5654)
BIOSECURE Act (6)
Biosimilars (92)
Biotechnology (21)
Bladder cancer (113)
Brain cancer (34)
Breast cancer (376)
Cancer (2814)
Cardiovascular disease (225)
Career advice (391)
Career pathing (11)
CAR-T (168)
CDC (16)
Cell therapy (404)
Cervical cancer (23)
Clinical research (32643)
Collaboration (891)
Company closure (2)
Compensation (230)
Complete response letters (34)
COVID-19 (1297)
CRISPR (49)
C-suite (304)
Cystic fibrosis (90)
Data (3580)
Denatured (5)
Depression (72)
Diabetes (306)
Diagnostics (2859)
Digital health (18)
Diversity (3)
Diversity, equity & inclusion (13)
Drug discovery (112)
Drug pricing (130)
Drug shortages (27)
Duchenne muscular dystrophy (113)
Earnings (35886)
Editorial (31)
Employer branding (6)
Employer resources (42)
Events (33924)
Executive appointments (370)
FDA (11801)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (2)
Frontotemporal dementia (8)
Funding (596)
Gene editing (114)
Generative AI (17)
Gene therapy (291)
GLP-1 (759)
Government (1699)
Grass and pollen (5)
Guidances (294)
Healthcare (6958)
HIV (34)
Huntington's disease (20)
IgA nephropathy (41)
Immunology and inflammation (144)
Immuno-oncology (39)
Indications (72)
Infectious disease (1461)
Inflammatory bowel disease (105)
Inflation Reduction Act (8)
Influenza (77)
Intellectual property (169)
Interviews (90)
IPO (7163)
IRA (30)
Job creations (1254)
Job search strategy (320)
JPM (30)
Kidney cancer (13)
Labor market (21)
Layoffs (243)
Leadership (14)
Legal (2417)
Liver cancer (37)
Longevity (7)
Lung cancer (389)
Lymphoma (247)
Machine learning (22)
Management (16)
Manufacturing (396)
MASH (98)
Medical device (6646)
Medtech (6662)
Mergers & acquisitions (7936)
Metabolic disorders (900)
Multiple sclerosis (103)
NASH (16)
Neurodegenerative disease (204)
Neuropsychiatric disorders (55)
Neuroscience (1579)
Neurotech (1)
NextGen: Class of 2026 (2173)
Non-profit (1317)
Now hiring (40)
Obesity (490)
Opinion (125)
Ovarian cancer (117)
Pain (111)
Pancreatic cancer (120)
Parkinson's disease (156)
Partnered (8)
Patents (327)
Patient recruitment (232)
Peanut (30)
People (17521)
Pharmaceutical (10)
Pharmacy benefit managers (13)
Phase 1 (9434)
Phase 2 (13878)
Phase 3 (12342)
Pipeline (3445)
Policy (157)
Postmarket research (1014)
Preclinical (3517)
Press Release (46)
Prostate cancer (144)
Psychedelics (25)
Radiopharmaceuticals (146)
Rare diseases (466)
Real estate (1463)
Recruiting (15)
Regulatory (11835)
Reports (22)
Research institute (789)
Resumes & cover letters (73)
Rett syndrome (18)
RNA editing (4)
RSV (55)
Schizophrenia (95)
Series A (100)
Series B (81)
Service/supplier (2)
Sickle cell disease (44)
Special edition (11)
Spinal muscular atrophy (76)
Sponsored (19)
Startups (941)
State (1)
Stomach cancer (11)
Supply chain (58)
Tariffs (65)
The Weekly (73)
Vaccines (497)
Venture capital (35)
Weight loss (393)
Women's health (57)
Date
Today (90)
Last 7 days (341)
Last 30 days (1137)
Last 365 days (15188)
2026 (1979)
2025 (15399)
2024 (17063)
2023 (18742)
2022 (23578)
2021 (23647)
2020 (21931)
2019 (16941)
2018 (13057)
2017 (13228)
2016 (11506)
2015 (14058)
2014 (9634)
2013 (7086)
2012 (7616)
2011 (8428)
2010 (7318)
Location
Africa (235)
Alabama (54)
Alaska (3)
Arizona (92)
Arkansas (6)
Asia (16416)
Australia (2339)
California (5609)
Canada (1121)
China (470)
Colorado (256)
Connecticut (272)
Delaware (193)
Europe (31611)
Florida (973)
Georgia (199)
Hawaii (1)
Idaho (16)
Illinois (378)
India (32)
Indiana (368)
Iowa (3)
Japan (428)
Kansas (83)
Kentucky (7)
Louisiana (7)
Maine (47)
Maryland (697)
Massachusetts (3760)
Michigan (113)
Minnesota (300)
Mississippi (3)
Missouri (39)
Montana (9)
Nebraska (8)
Nevada (73)
New Hampshire (34)
New Jersey (1997)
New Mexico (5)
New York (1598)
North Carolina (732)
North Dakota (3)
Northern California (2692)
Ohio (166)
Oklahoma (4)
Oregon (12)
Pennsylvania (1119)
Puerto Rico (17)
Rhode Island (11)
South America (309)
South Carolina (51)
Southern California (2261)
Tennessee (57)
Texas (1096)
United States (20628)
Utah (188)
Virginia (165)
Washington D.C. (47)
Washington State (490)
West Virginia (2)
Wisconsin (53)
Wyoming (1)
263,390 Results for "eli lilly japan k k".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Manufacturing
Eli Lilly Commits $3.5B To Build Injectable Obesity Drug Plant in PA
The facility, which is part of Lilly’s $50 billion reshoring drive, will make obesity drugs such as tirzepatide and retatrutide when it starts operations in 2031.
February 2, 2026
·
2 min read
·
Nick Paul Taylor
Mergers & acquisitions
Rumors of Eli Lilly Buyout Send Nektar’s Shares Spiking
Several sources are speculating that the potential buyer could be Eli Lilly, despite the breakdown of the pharma’s partnership with Nektar over atopic dermatitis therapy rezpeg.
October 20, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Eli Lilly Enters CAR T Realm With $2.4B Orna Buy, Starting With Autoimmune
The deal gets Lilly access to Orna’s in vivo CAR T technology. The biotech’s lead asset, which has yet to start clinical testing, is focused on B cell–driven autoimmune diseases.
February 9, 2026
·
2 min read
·
Dan Samorodnitsky
Gene editing
Lilly Leans Into Hearing Loss in $1.12B+ Gene Editing Pact With Seamless
The deal will help bolster Eli Lilly’s growing hearing loss portfolio, which is anchored by the gene therapy AK-OTOF.
January 28, 2026
·
2 min read
·
Tristan Manalac
Editorial
Novo Will Never Beat Lilly. Why Does It Have To?
Novo Nordisk and Eli Lilly have been battling head-to-head in an exploding obesity market. They should never have been compared apples to apples.
February 5, 2026
·
3 min read
·
Annalee Armstrong
Weight Loss
Lilly’s Path to $94B in Revenue Rests on Oral Obesity Market and Other 2026 Milestones
The fierce rivalry between Novo Nordisk and Eli Lilly is alive and well, as the two companies are expected to face off with their new obesity pills this year.
January 5, 2026
·
3 min read
·
Annalee Armstrong
Obesity
Lilly Prepares $1B+ Orforglipron Stock Ahead of Approval as Novo Brings Wegovy Pill Overseas
Eli Lilly has long been gearing up for the launch of orforglipron, announcing as early as February 2024 that it was ramping up manufacturing investments for the weight-loss pill.
February 13, 2026
·
2 min read
·
Tristan Manalac
pipeline
Lilly Axes 3 Therapies Amid Pipeline-in-a-Product Push for GLP-1
One of the assets shelved by Eli Lilly is a gene therapy for dementia, which it obtained in its $1.04-billion acquisition of Prevail Therapeutics in late 2020.
February 5, 2026
·
2 min read
·
Tristan Manalac
Obesity
Lilly’s Obesity Pill Maintains Weight Loss as Estimated Approval Timelines Inch Closer
Participants in a Phase III trial who switched to Eli Lilly’s orforglipron after 72 weeks of treatment with Wegovy or Zepbound largely maintained their weight loss for up to a year.
December 18, 2025
·
2 min read
·
Tristan Manalac
Podcast
Weight Loss Drama Compounds on Heels of Novo, Lilly Earnings, Plus Gene Therapy News
A lawsuit and FDA warning ensued after Hims & Hers launched a compounded version of Novo Nordisk’s new obesity pill, more Big Pharma report earnings—including from weight loss rivals Novo and Eli Lilly—and the gene therapy space sees another rejection.
February 11, 2026
·
1 min read
·
Jef Akst
1 of 26,339
Next
